Key Takeaways
- BioMarin and Ascendis Pharma finalized a comprehensive settlement ending worldwide patent litigation concerning Ascendis’s Yuviwel drug.
- BioMarin will receive 20% royalties on Yuviwel’s U.S. net revenues and 18% on sales across the EU, Brazil, and South Korea.
- Payment terms extend retroactively from Yuviwel’s initial commercial launch through May 2030.
- The licensing agreement encompasses all existing and future therapeutic applications of Yuviwel, including treatments for achondroplasia and hypochondroplasia.
- BioMarin agreed to withdraw its Section 337 complaint with the ITC and terminate related lawsuits in multiple jurisdictions.
On August 30, 2026, BioMarin Pharmaceutical (BMRN) announced a comprehensive worldwide patent agreement with Ascendis Pharma, bringing closure to an extensive legal dispute centered on CNP technology utilized in Ascendis’s therapeutic product Yuviwel. At the time of this announcement, BMRN stock experienced a 0.96% decline.
BioMarin Pharmaceutical Inc., BMRN
The pharmaceutical companies had been engaged in contentious legal proceedings spanning numerous global jurisdictions, including a significant case before the U.S. International Trade Commission. This comprehensive settlement resolves all outstanding matters through a single unified agreement.
According to the settlement terms, Ascendis has committed to paying BioMarin royalties equivalent to 20% of Yuviwel’s net revenues generated in the United States, with these payments applying retroactively from the product’s initial commercial launch date. For markets in the European Union, Brazil, and South Korea, the royalty percentage is set at 18% of net sales. These payment obligations continue through May 2030.
The licensing arrangement provides comprehensive coverage for Yuviwel across all existing and prospective therapeutic applications, encompassing achondroplasia, hypochondroplasia, and potential combination treatment approaches. This expansive framework ensures BioMarin’s intellectual property protection extends significantly beyond the primary medical indication.
Terms of the Settlement Agreement
As part of the agreement, BioMarin committed to withdrawing its Section 337 complaint filed with the ITC. Additionally, ongoing legal proceedings in Brazil, Denmark, Germany, South Korea, and California’s Northern District will be dismissed.
Ascendis further committed to refraining from any challenges to BioMarin’s patent rights and consented to a bilateral regulatory non-interference provision. This represents a significant strategic concession from Ascendis’s perspective.
The agreement reinforces the value of BioMarin’s CNP technology platform, which forms the foundation for its proprietary medication VOXZOGO (vosoritide), approved for treating children diagnosed with achondroplasia. BioMarin invested considerable resources over many years in developing this foundational scientific platform, and the royalty arrangement represents a tangible financial return on that research investment.
BioMarin’s Strategic Standing in Rare Disease Treatment
Alexander Hardy, BioMarin’s CEO, characterized the settlement as evidence that sustained investment in rare disease therapeutic innovation yields meaningful results. The pharmaceutical company currently markets nine commercial products and has pioneered six first-in-disease treatment options.
Current analyst consensus rates BMRN as a Buy with an $88.00 price target. The company maintains a market capitalization of approximately $12.52 billion.
From a technical perspective, BioMarin’s stock sentiment registers as a Buy, with current trading prices positioned above key moving averages and exhibiting positive MACD indicators. However, financial analysts have noted recent declines in profitability metrics and return on equity, alongside an elevated P/E ratio valuation.
During its latest earnings presentation, the company increased its 2026 revenue projections, providing positive momentum as the company progresses through the year’s second half.
This settlement establishes an additional royalty-based revenue stream connected to Yuviwel sales performance across four significant international markets, contributing to BioMarin’s financial results through the May 2030 expiration date.
The post BioMarin (BMRN) Stock Secures Victory in Patent Dispute, Gains Royalty Stream Through 2030 appeared first on Blockonomi.
Be the first to comment